Prakash Vishnu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Prakash Vishnu has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- Euphemia Leung
Auckland Cancer Society Research Centre, University of Auckland, Grafton, Auckland 1023, New Zealand
7 shared publications - Geoffrey Wayne Krissansen
Department of Molecular Medicine & Pathology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
7 shared publications - Jiwon Hong
School of Biological Sciences Faculty of Science University of Auckland Auckland New Zealand
7 shared publications - Tony Raymond Merriman
Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
7 shared publications - David Michael Aboulafia
Virginia Mason Medical Center
6 shared publications Alan G Fraser
Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland and
4 shared publications
Latest Publications
- Open Access
- 31 October 2023
- Published by Adichunchanagiri Institute of Medical Sciences in Journal of Medical Sciences and Health
- Vol. 9 (2) , 237-240
COVID-19 Vaccination-Associated Spontaneous Heparin-Induced Thrombocytopenia Syndrome
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has emerged as the deadliest outbreak in recent American history, surpassing the estimated U.S. fatalities from the 1918 influenza pandemic. Since its identification in December 2019 in Wuhan, China, COVID-19 has contributed to the death of nearly six million people worldwide. The United States (U.S.) Food and Drug Administration (FDA) initially issued emergency use authorization for three vaccines for prevention of COVID-19, and currently two have received full FDA approval. Herein, we report a case of severe thrombocytopenia in a man following heterologous booster vaccination with the Pfizer-BioNTech COVID-19 vaccine with concomitant presence of a heparin-P4 antibody but without proximate heparin exposure. The degree of thrombocytopenia was severe, but the patient had a natural recovery of platelet count over the next 2 weeks without need for any immunomodulatory therapies. This is the first case report of COVID vaccine-associated heparin-induced thrombocytopenia (HIT)-like platelet disorder without proximate heparin exposure, also called spontaneous HIT syndrome. Keywords: Thrombocytopenia, Coronavirus disease 2019, COVID19 vaccine, Heparin induced thrombocyotpenia, Spontaneous HIT syndrome
- 31 October 2023
- Published by Adichunchanagiri Institute of Medical Sciences in Journal of Medical Sciences and Health
- Vol. 9 (2) , 237-240
Open AccessCOVID-19 Vaccination-Associated Spontaneous Heparin-Induced Thrombocytopenia Syndrome
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has emerged as the deadliest outbreak in recent American history, surpassing the estimated U.S. fatalities from the 1918 influenza pandemic. Since its identification in December 2019 in Wuhan, China, COVID-19 has contributed to the death of nearly six million people worldwide. The United States (U.S.) Food and Drug Administration (FDA) initially issued emergency use authorization for three vaccines for prevention of COVID-19, and currently two have received full FDA approval. Herein, we report a case of severe thrombocytopenia in a man following heterologous booster vaccination with the Pfizer-BioNTech COVID-19 vaccine with concomitant presence of a heparin-P4 antibody but without proximate heparin exposure. The degree of thrombocytopenia was severe, but the patient had a natural recovery of platelet count over the next 2 weeks without need for any immunomodulatory therapies. This is the first case report of COVID vaccine-associated heparin-induced thrombocytopenia (HIT)-like platelet disorder without proximate heparin exposure, also called spontaneous HIT syndrome. Keywords: Thrombocytopenia, Coronavirus disease 2019, COVID19 vaccine, Heparin induced thrombocyotpenia, Spontaneous HIT syndrome
- Open Access
- 6 October 2023
- Published by Scientific Scholar in Journal of Clinical Imaging Science
- Vol. 3, 136
Bullous dermatophytosis
- 6 October 2023
- Published by Scientific Scholar in Journal of Clinical Imaging Science
- Vol. 3, 136
Open AccessBullous dermatophytosis
- Open Access
- 1 December 2019
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 3 (4) , 485-494
Quality Initiative in Clinical Practice: A Single-Institution Appraisal of Quality Metrics in the Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma
- 1 December 2019
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 3 (4) , 485-494
Open AccessQuality Initiative in Clinical Practice: A Single-Institution Appraisal of Quality Metrics in the Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma
- 1 November 2019
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 94 (11) , 2199-2208
Sequence of Splenectomy and Rituximab for the Treatment of Steroid-Refractory Immune Thrombocytopenia: Does It Matter?
- 1 November 2019
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 94 (11) , 2199-2208
Sequence of Splenectomy and Rituximab for the Treatment of Steroid-Refractory Immune Thrombocytopenia: Does It Matter?
- 1 August 2019
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 94 (8) , 1542-1550
Etiologies of Extreme Thrombocytosis: A Contemporary Series
- 1 August 2019
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 94 (8) , 1542-1550
Etiologies of Extreme Thrombocytosis: A Contemporary Series
- 19 March 2019
- Published by Georg Thieme Verlag KG in Hamostaseologie
- Vol. 39 (03) , 279-283
Management of Helicobacter pylori in Patients with Immune Thrombocytopenia
There is an association between Helicobacter pylori infection and immune thrombocytopenia (ITP), and few studies have suggested that eradicative treatment of H. pylori infection may improve platelet counts in patients with ITP. Conventional treatments for ITP include immunosuppressive agents, and more recently thrombopoietic agents. However, based on clinical reports of association between H. pylori and ITP, several medical societies increasingly suggest detection and eradication of H. pylori as a treatment for ITP. In this article, we reappraise recent medical literature to determine the effectiveness of platelet response after treatment of H. pylori infection in patients with ITP. We searched two online databases (MEDLINE and Google Scholar) for full articles published between January 2008 and May 2018, and found a total of 11 studies that presented data and outcomes of treatment of H. pylori infection in ITP patients. All the studies administered triple therapy (amoxicillin 500 mg, clarithromycin 250 mg and a proton-pump inhibitor each given twice daily for either 7- or 14-day course) for eradication of H. pylori. Median overall platelet response ranged from 27 to 69.2% with a complete response rate ranging from 0 to 65.4% and a partial response rate ranging from 0 to 29.4%. Although there is variability in the effectiveness between different populations, it appears to be of benefit to ITP patients with concomitant H. pylori infection when treated with triple therapy. However, further studies to understand the pathogenesis of H. pylori-associated ITP is necessary for the development of new therapeutic approaches for ITP.
- 19 March 2019
- Published by Georg Thieme Verlag KG in Hamostaseologie
- Vol. 39 (03) , 279-283
Management of Helicobacter pylori in Patients with Immune Thrombocytopenia
There is an association between Helicobacter pylori infection and immune thrombocytopenia (ITP), and few studies have suggested that eradicative treatment of H. pylori infection may improve platelet counts in patients with ITP. Conventional treatments for ITP include immunosuppressive agents, and more recently thrombopoietic agents. However, based on clinical reports of association between H. pylori and ITP, several medical societies increasingly suggest detection and eradication of H. pylori as a treatment for ITP. In this article, we reappraise recent medical literature to determine the effectiveness of platelet response after treatment of H. pylori infection in patients with ITP. We searched two online databases (MEDLINE and Google Scholar) for full articles published between January 2008 and May 2018, and found a total of 11 studies that presented data and outcomes of treatment of H. pylori infection in ITP patients. All the studies administered triple therapy (amoxicillin 500 mg, clarithromycin 250 mg and a proton-pump inhibitor each given twice daily for either 7- or 14-day course) for eradication of H. pylori. Median overall platelet response ranged from 27 to 69.2% with a complete response rate ranging from 0 to 65.4% and a partial response rate ranging from 0 to 29.4%. Although there is variability in the effectiveness between different populations, it appears to be of benefit to ITP patients with concomitant H. pylori infection when treated with triple therapy. However, further studies to understand the pathogenesis of H. pylori-associated ITP is necessary for the development of new therapeutic approaches for ITP.
- Open Access
- 5 September 2018
- Published by MDPI AG in Hematology Reports
- Vol. 10 (3) , 59-61
Myelodysplasia-related acute myeloid leukemia and acute promyelocytic leukemia: concomitant occurrence of two molecularly distinct diseases
Concurrent presentation of acute promyelocytic leukemia (APL) with other hematologic diseases in the absence of previous chemotherapy or ionizing radiotherapy treatment is very rare. We present a case of simultaneous occurrence of APL with myelodysplastic syndrome (MDS)-related acute myeloid leukemia (AML). A 43-year-old female presented with 3 month of history fatigue, night sweats, chills and pancytopenia. Bone marrow aspirate and biopsy demonstrated 20% myeloid blasts with dysplastic changes admixed with abnormal promyelocytes. Cytogenetic analysis showed tetraploidy and deletion in chromosomes 5q and 7q and polymerase chain reaction showed presence of PML/RARA mRNA transcripts, confirming the presence of concurrent APL and MDS-related AML. Induction chemotherapy with cytarabine and daunorubicin was initiated along with all-trans retinoic acid. This is the first case to be reported in the literature of concurrent occurrence of APL with MDS-related AML. Treatment with 7 + 3 regimen and ATRA was successful in inducing complete remission.
- 5 September 2018
- Published by MDPI AG in Hematology Reports
- Vol. 10 (3) , 59-61
Open AccessMyelodysplasia-related acute myeloid leukemia and acute promyelocytic leukemia: concomitant occurrence of two molecularly distinct diseases
Concurrent presentation of acute promyelocytic leukemia (APL) with other hematologic diseases in the absence of previous chemotherapy or ionizing radiotherapy treatment is very rare. We present a case of simultaneous occurrence of APL with myelodysplastic syndrome (MDS)-related acute myeloid leukemia (AML). A 43-year-old female presented with 3 month of history fatigue, night sweats, chills and pancytopenia. Bone marrow aspirate and biopsy demonstrated 20% myeloid blasts with dysplastic changes admixed with abnormal promyelocytes. Cytogenetic analysis showed tetraploidy and deletion in chromosomes 5q and 7q and polymerase chain reaction showed presence of PML/RARA mRNA transcripts, confirming the presence of concurrent APL and MDS-related AML. Induction chemotherapy with cytarabine and daunorubicin was initiated along with all-trans retinoic acid. This is the first case to be reported in the literature of concurrent occurrence of APL with MDS-related AML. Treatment with 7 + 3 regimen and ATRA was successful in inducing complete remission.
- 28 June 2018
- Published by BMJ in BMJ Case Reports
- Vol. 2018
Post-transplant erythrocytosis refractory to ACE inhibitors and angiotensin receptor blockers
Post-transplant erythrocytosis (PTE) is a condition with elevated haematocrit (hct) in renal allograft recipients. The mainstay of treatment is ACE inhibitors (ACEi) or angiotensin II receptor blockers (ARB), but seldom phlebotomy. PTE must be recognised early to prevent major thromboembolic events. We present a case of PTE that was refractory to blockade of renin–angiotensin system (RAS) by ACEi and ARB and required phlebotomy for control of hct. Our review of medical literature about prevalence and pathophysiology of PTE suggests that approximately 22% of patients with PTE are refractory to ACEi/ARB treatment. There are four plausible pathways that appear to play a role in causing PTE: disruption of erythropoietin regulation, mitogenic effect of the RAS on erythroid lineage, insulin-like growth factor 1 and androgenic stimulation. Presently, there is no unifying hypothesis involving these factors, but refractoriness to ACEi/ARB may represent a distinct subcategory of PTE.
- 28 June 2018
- Published by BMJ in BMJ Case Reports
- Vol. 2018
Post-transplant erythrocytosis refractory to ACE inhibitors and angiotensin receptor blockers
Post-transplant erythrocytosis (PTE) is a condition with elevated haematocrit (hct) in renal allograft recipients. The mainstay of treatment is ACE inhibitors (ACEi) or angiotensin II receptor blockers (ARB), but seldom phlebotomy. PTE must be recognised early to prevent major thromboembolic events. We present a case of PTE that was refractory to blockade of renin–angiotensin system (RAS) by ACEi and ARB and required phlebotomy for control of hct. Our review of medical literature about prevalence and pathophysiology of PTE suggests that approximately 22% of patients with PTE are refractory to ACEi/ARB treatment. There are four plausible pathways that appear to play a role in causing PTE: disruption of erythropoietin regulation, mitogenic effect of the RAS on erythroid lineage, insulin-like growth factor 1 and androgenic stimulation. Presently, there is no unifying hypothesis involving these factors, but refractoriness to ACEi/ARB may represent a distinct subcategory of PTE.
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
365 - Hepatic Iron Overload Identified by Magnetic Resonance Imaging-Based T2* is a Predictor of Inadequate Hepatic Elastography
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
365 - Hepatic Iron Overload Identified by Magnetic Resonance Imaging-Based T2* is a Predictor of Inadequate Hepatic Elastography
- 23 March 2018
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 59 (11) , 2727-2730
Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience
A subset of marginal zone lymphoma (MZL) has an aggressive clinical course and role of allogeneic hematopoietic cell transplant (allo-HCT) is not well defined for these patients. MZL includes three...
- 23 March 2018
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 59 (11) , 2727-2730
Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience
A subset of marginal zone lymphoma (MZL) has an aggressive clinical course and role of allogeneic hematopoietic cell transplant (allo-HCT) is not well defined for these patients. MZL includes three...